| Literature DB >> 26627015 |
Stephen Q Wong1, Kelly Waldeck1, Ismael A Vergara1, Jan Schröder2, Jason Madore3, James S Wilmott3, Andrew J Colebatch4, Ricardo De Paoli-Iseppi3, Jason Li1, Richard Lupat1, Timothy Semple1, Gisela Mir Arnau1, Andrew Fellowes1, J Helen Leonard5, George Hruby3, Graham J Mann3, John F Thompson3, Carleen Cullinane1, Meredith Johnston1, Mark Shackleton6, Shahneen Sandhu6, David D L Bowtell7, Ricky W Johnstone6, Stephen B Fox7, Grant A McArthur6, Anthony T Papenfuss8, Richard A Scolyer3, Anthony J Gill9, Rodney J Hicks6, Richard W Tothill10.
Abstract
Merkel cell carcinoma (MCC) is an uncommon, but highly malignant, cutaneous tumor. Merkel cell polyoma virus (MCV) has been implicated in a majority of MCC tumors; however, viral-negative tumors have been reported to be more prevalent in some geographic regions subject to high sun exposure. While the impact of MCV and viral T-antigens on MCC development has been extensively investigated, little is known about the etiology of viral-negative tumors. We performed targeted capture and massively parallel DNA sequencing of 619 cancer genes to compare the gene mutations and copy number alterations in MCV-positive (n = 13) and -negative (n = 21) MCC tumors and cell lines. We found that MCV-positive tumors displayed very low mutation rates, but MCV-negative tumors exhibited a high mutation burden associated with a UV-induced DNA damage signature. All viral-negative tumors harbored mutations in RB1, TP53, and a high frequency of mutations in NOTCH1 and FAT1. Additional mutated or amplified cancer genes of potential clinical importance included PI3K (PIK3CA, AKT1, PIK3CG) and MAPK (HRAS, NF1) pathway members and the receptor tyrosine kinase FGFR2. Furthermore, looking ahead to potential therapeutic strategies encompassing immune checkpoint inhibitors such as anti-PD-L1, we also assessed the status of T-cell-infiltrating lymphocytes (TIL) and PD-L1 in MCC tumors. A subset of viral-negative tumors exhibited high TILs and PD-L1 expression, corresponding with the higher mutation load within these cancers. Taken together, this study provides new insights into the underlying biology of viral-negative MCC and paves the road for further investigation into new treatment opportunities. ©2015 American Association for Cancer Research.Entities:
Mesh:
Year: 2015 PMID: 26627015 DOI: 10.1158/0008-5472.CAN-15-1877
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701